All Stories

  1. Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH

    Article • Scientific Reports, December 2019, Springer Science + Business Media

    Dr Joan Genesca

  2. Beyond Baveno VI: How far are we?

    Article • Digestive and Liver Disease, August 2019, Elsevier

    Dr Joan Genesca

  3. Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study

    Article • Hepatology, December 2018, Wiley

    Dr Joan Genesca, Clinical Chair Professor Henning Gronbaek

  4. Should prophylactic embolization of spontaneous portosystemic shunts be routinely performed during transjugular intrahepatic portosystemic shunt placement?

    Article • Digestive and Liver Disease, June 2018, Elsevier

    Dr Joan Genesca

  5. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis

    Article • Hepatology, February 2018, Wiley

    Dr Joan Genesca

  6. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients

    Article • Therapeutic Advances in Gastroenterology, November 2017, SAGE Publications

    Dr Joan Genesca

  7. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease

    Article • Hepatology, October 2017, Wiley

    Dr Joan Genesca

  8. Correction

    Article • Hepatology, June 2017, Wiley

    Dr Joan Genesca

  9. Enfermedades vasculares del hígado. Guías Clínicas de la Sociedad Catalana de Digestología y de la Asociación Española para el Estudio del Hígado

    Article • Gastroenterología y Hepatología, June 2017, Elsevier

    Dr Joan Genesca

  10. Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding

    Article • Clinical Gastroenterology and Hepatology, May 2017, Elsevier

    Dr Joan Genesca

  11. Risk Stratification in Acute Variceal Bleeding

    Article • Journal of Clinical Gastroenterology, April 2017, Wolters Kluwer Health

    Dr Joan Genesca

  12. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study

    Article • Hepatology, March 2017, Wiley

    Dr Joan Genesca

  13. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping

    Article • Clinical Microbiology and Infection, February 2017, Elsevier

    Dr Joan Genesca

  14. Validating the Baveno VI recommendations for screening varices

    Article • Journal of Hepatology, February 2017, Elsevier

    Dr Joan Genesca

  15. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats

    Article • Scientific Reports, January 2017, Nature

    Dr Joan Genesca

  16. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis

    Article • Liver International, November 2016, Wiley

    Dr Joan Genesca, Clinical Chair Professor Henning Gronbaek

  17. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study

    Article • Hepatology, October 2016, Wiley

    Dr Joan Genesca

  18. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients

    Article • Therapeutic Advances in Gastroenterology, July 2016, SAGE Publications

    Dr Joan Genesca, Dr Beatriz Mínguez

  19. Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy

    Article • Journal of Cerebral Blood Flow & Metabolism, July 2016, SAGE Publications

    Laia Chavarria, Dr Joan Genesca

  20. Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease

    Article • Digestive and Liver Disease, June 2016, Elsevier

    Dr Joan Genesca

  21. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis

    Article • Gastroenterology, May 2016, Elsevier

    Dr Joan Genesca, Dr Juan G Abraldes

  22. Ruling in and ruling out with elastography in compensated advanced chronic liver disease

    Article • Gut, March 2016, BMJ

    Dr Joan Genesca

  23. α1 and α2-adrenergic agonists on cirrhotic patients with refractory ascites

    Article • Liver International, January 2016, Wiley

    Dr Joan Genesca

  24. Consensus Statements: Session 1—Screening and Surveillance

    Article • January 2016, Springer Science + Business Media

    Dr Joan Genesca

  25. Identifying Compensated Advanced Chronic Liver Disease: When (Not) to Start Screening for Varices and Clinically Significant Portal Hypertension

    Article • January 2016, Springer Science + Business Media

    Dr Joan Genesca

  26. Erratum to: Chapter 9 in Consensus Statements: Session 1—Screening and Surveillance

    Article • January 2016, Springer Science + Business Media

    Dr Joan Genesca

  27. Evaluación y tratamiento del paciente cirrótico crítico

    Article • Gastroenterología y Hepatología, January 2016, Elsevier

    Dr Joan Genesca

  28. Alcohol consumption and risk of infection after a variceal bleeding in low-risk patients

    Article • Liver International, December 2015, Wiley

    Dr Joan Genesca

  29. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension

    Article • Hepatology, November 2015, Wiley

    Dr Joan Genesca

  30. Reply to “Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno’s VI consensus”

    Article • Journal of Hepatology, October 2015, Elsevier

    Dr Joan Genesca

  31. Expanding consensus in portal hypertension

    Article • Journal of Hepatology, September 2015, Elsevier

    Dr Joan Genesca

  32. Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study

    Article • Hepatology, April 2015, Wiley

    Professor Juan Carlos Garcia-Pagán, Dr Joan Genesca

  33. O017A : Non-invasive tools and risk of varices and clinically significant portal hypertension in compensated cirrhosis: the “anticipate” study

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Joan Genesca

  34. P0102 : Degeneration signs of Purkinje neurons in a new animal model of episodic hepatic encephalopathy

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Joan Genesca

  35. Reply

    Article • Hepatology, September 2014, Wolters Kluwer Health

    Dr Joan Genesca

  36. O167 ADDITION OF SIMVASTATIN TO STANDARD TREATMENT IMPROVES SURVIVAL AFTER VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS. A DOUBLE-BLIND RANDOMIZED TRIAL (NCT01095185)

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Joan Genesca

  37. Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: A prospective study

    Article • Journal of Hepatology, March 2014, Elsevier

    Dr Joan Genesca

  38. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats

    Article • Liver International, February 2014, Wiley

    Dr Joan Genesca

  39. A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding

    Article • Gastroenterology, February 2014, Elsevier

    Dr Juan G Abraldes, Dr Joan Genesca

  40. Inhibition of Neuronal Apoptosis and Axonal Regression Ameliorates Sympathetic Atrophy and Hemodynamic Alterations in Portal Hypertensive Rats

    Article • PLoS ONE, January 2014, PLOS

    Dr Joan Genesca

  41. Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study

    Article • Hepatology, October 2013, Wiley

    Dr Juan G Abraldes, Dr Joan Genesca

  42. 602 HEMODYNAMIC EFFECTS OF A COMBINED ACUTE TREATMENT WITH A NON-SELECTIVE BETA BLOCKER PLUS DROXIDOPA IN CIRRHOTIC RATS

    Article • Journal of Hepatology, April 2013, Elsevier

    Dr Joan Genesca

  43. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats

    Article • Hepatology, October 2012, Wiley

    Dr Joan Genesca

  44. Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding

    Article • Hepatology, July 2012, Wiley

    Dr Joan Genesca

  45. Hipertensión portal: recomendaciones para su evaluación y tratamiento

    Article • Gastroenterología y Hepatología, June 2012, Elsevier

    Dr Juan G Abraldes, Dr Joan Genesca

  46. 574 ALTERED NEUROMODULATOR EXPRESION WITHIN THE SUPERIOR MESENTERIC GANGLIA MAY CAUSE SYMPATHETIC ATROPHY IN PORTAL HYPERTENSIVE RATS

    Article • Journal of Hepatology, April 2012, Elsevier

    Dr Joan Genesca

  47. 609 A SIMPLE DIAGNOSTIC STRATEGY BASED ON ROUTINE CLINICAL DATA AND TRANSIENT ELASTOGRAPHY ACCURATELY DETECTS EARLY PORTAL HYPERTENSION IN PATIENTS WITH ASYMPTOMATIC LIVER DISEASE

    Article • Journal of Hepatology, April 2012, Elsevier

    Dr Joan Genesca

  48. Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension

    Article • Liver International, January 2012, Wiley

    Dr Joan Genesca

  49. Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy

    Article • Digestive and Liver Disease, January 2012, Elsevier

    Dr Joan Genesca

  50. Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding

    Article • The American Journal of Gastroenterology, May 2011, Wolters Kluwer Health

    Dr Joan Genesca

  51. 598 HEMODYNAMIC AND RENAL EFFECTS OF AN ORAL PRODRUG OF NOREPINEPHRINE IN PORTAL HYPERTENSIVE RATS

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Joan Genesca

  52. 597 EFFECT OF NEONATAL CAPSAICIN TREATMENT ON SYMPATHETIC ATROPHY AND HEMODYNAMIC ALTERATIONS OF PORTAL HYPERTENSIVE RATS

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Joan Genesca

  53. 934 LONG-TERM FOLLOW-UP OF HEMODYNAMIC RESPONDERS TO PHARMACOLOGICAL THERAPY AFTER VARICEAL BLEEDING: A COHORT-STUDY

    Article • Journal of Hepatology, March 2011, Elsevier

    Dr Joan Genesca

  54. Diagnostic and Prognostic Markers in Liver Cirrhosis

    Article • Disease Markers, January 2011, Hindawi Publishing Corporation

    Dr Joan Genesca

  55. Prognostic Evaluation of Patients with Acute Variceal Bleeding

    Article • Disease Markers, January 2011, Hindawi Publishing Corporation

    Dr Joan Genesca

  56. High doses of β-blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding

    Article • Liver International, May 2010, Wiley

    Dr Joan Genesca

  57. Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension

    Article • Liver International, April 2010, Wiley

    Dr Joan Genesca

  58. 509 THE ABLATION OF THE AFFERENT SENSITIVE PATHWAY PREVENTS SYMPATHETIC ATROPHY AND HEMODYNAMIC ALTERATIONS DURING PORTAL HYPERTENSION

    Article • Journal of Hepatology, April 2010, Elsevier

    Dr Joan Genesca

  59. 840 ENDOSCOPIC VARICEAL LIGATION IS HIGHLY EFFECTIVE IN THE PREVENTION OF VARICEAL REBLEEDING IN HEMODYNAMIC NON-RESPONDERS TO PHARMACOLOGICAL THERAPY

    Article • Journal of Hepatology, April 2010, Elsevier

    Dr Joan Genesca

  60. Physiopathology of splanchnic vasodilation in portal hypertension

    Article • World Journal of Hepatology, January 2010, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Joan Genesca

  61. Acute esophageal variceal bleeding: Current strategies and new perspectives

    Article • World Journal of Hepatology, January 2010, Baishideng Publishing Group Co., Limited (formerly WJG Press)

    Dr Joan Genesca

  62. Predicting Early Mortality After Acute Variceal Hemorrhage Based on Classification and Regression Tree Analysis

    Article • Clinical Gastroenterology and Hepatology, December 2009, Elsevier

    Dr Joan Genesca

  63. 208 LONG-TERM OUTCOME OF CIRRHOTIC PATIENTS AFTER AN EPISODE OF VARICEAL BLEEDING: ANALYSIS OF PROGNOSTIC FACTORS

    Article • Journal of Hepatology, April 2009, Elsevier

    Dr Joan Genesca

  64. 176 PROGNOSTIC ASSESSMENT OF EARLY MORTALITY AFTER ACUTE VARICEAL HAEMORRHAGE BASED ON CLASSIFICATION AND REGRESSION TREE ANALYSIS

    Article • Journal of Hepatology, April 2009, Elsevier

    Dr Joan Genesca

  65. Disappearance of serum hepatitis B virus DNA by polymerase chain reaction after adenine arabinoside 5‘-monophosphate therapy in chronic hepatitis B

    Article • Liver International, December 2008, Wiley

    Dr Joan Genesca

  66. Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis

    Article • European Journal of Gastroenterology & Hepatology, September 2008, Wolters Kluwer Health

    Dr Joan Genesca

  67. Valor del gradiente de presión hepática en el pronóstico de la cirrosis compensada

    Article • Gastroenterología y Hepatología Continuada, August 2008, Elsevier

    Dr Joan Genesca

  68. Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension

    Article • Journal of Hepatology, July 2008, Elsevier

    Dr Joan Genesca

  69. Response to Heish et al.

    Article • The American Journal of Gastroenterology, February 2008, Wolters Kluwer Health

    Dr Joan Genesca

  70. Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C

    Article • The American Journal of Gastroenterology, October 2007, Wolters Kluwer Health

    Dr Joan Genesca

  71. Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene

    Article • European Journal of Clinical Investigation, August 2007, Wiley

    Dr Joan Genesca

  72. Angiomiolipoma hepático en dos pacientes con infección por el virus de la hepatitis C

    Article • Gastroenterología y Hepatología, April 2007, Elsevier

    Dr Joan Genesca

  73. [190] INHIBITION OF ADRENERGIC TRANSMISSION MAY CONTRIBUTE TO SPLANCHNIC VASODILATION IN PORTAL HYPERTENSION

    Article • Journal of Hepatology, April 2007, Elsevier

    Dr Joan Genesca

  74. Sustained Virological Response Correlates With Reduction in the Incidence of Glucose Abnormalities in Patients With Chronic Hepatitis C Virus Infection

    Article • Diabetes Care, October 2006, American Diabetes Association

    Dr Joan Genesca

  75. Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C patients: A case-control study

    Article • Diabetes Care, May 2006, American Diabetes Association

    Dr Joan Genesca

  76. Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis

    Article • Diabetes Care, May 2006, American Diabetes Association

    Dr Joan Genesca

  77. Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis

    Article • Diabetes Care, April 2006, American Diabetes Association

    Dr Joan Genesca

  78. Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C patients: A case-control study

    Article • Diabetes Care, April 2006, American Diabetes Association

    Dr Joan Genesca

  79. Hemodynamic response–guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study

    Article • Hepatology, January 2006, Wiley

    Dr Joan Genesca

  80. Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection: Response to Sebastiani et al.

    Article • Diabetes Care, June 2005, American Diabetes Association

    Dr Joan Genesca

  81. Cardiac alterations in cirrhosis: reversibility after liver transplantation

    Article • Journal of Hepatology, January 2005, Elsevier

    Dr Joan Genesca

  82. Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection

    Article • Diabetes Care, October 2004, American Diabetes Association

    Dr Joan Genesca

  83. Validation of Automated Blood Cell Counters for the Diagnosis of Spontaneous Bacterial Peritonitis

    Article • The American Journal of Gastroenterology, July 2004, Wolters Kluwer Health

    Dr Joan Genesca

  84. High Prevalence of Glucose Abnormalities in Patients With Hepatitis C Virus Infection: A multivariate analysis considering the liver injury

    Article • Diabetes Care, April 2004, American Diabetes Association

    Dr Joan Genesca

  85. Citocinas y cirrosis hepática

    Article • Medicina Clínica, April 2004, Elsevier

    Dr Joan Genesca

  86. Citocinas y cirrosis hepática

    Article • Medicina Clínica, January 2004, Elsevier

    Dr Joan Genesca

  87. 213 Cirrhotic cardiomyopathy is reversible after liver transplantation

    Article • Journal of Hepatology, January 2004, Elsevier

    Dr Joan Genesca

  88. Increased tumour necrosis factor   production in mesenteric lymph nodes of cirrhotic patients with ascites

    Article • Gut, July 2003, BMJ

    Dr Joan Genesca

  89. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed

    Article • European Journal of Gastroenterology & Hepatology, July 2003, Wolters Kluwer Health

    Dr Joan Genesca

  90. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT

    Article • Hepatology, June 2003, Wiley

    Dr Joan Genesca

  91. Role of immunosuppression in the development of quinolone-resistant Escherichia coli spontaneous bacterial peritonitis and in the mortality of E. coli spontaneous bacterial peritonitis

    Article • Alimentary Pharmacology & Therapeutics, February 2003, Wiley

    Dr Joan Genesca

  92. Spontaneous bacterial peritonitis caused by quinolone-resistant Escherichia coli: could steroid therapy play a role?

    Article • European Journal of Gastroenterology & Hepatology, January 2002, Wolters Kluwer Health

    Dr Joan Genesca

  93. Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive β-blockers

    Article • Gastroenterology, October 2001, Elsevier

    Dr Joan Genesca

  94. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive β-blockers

    Article • Gastroenterology, October 2001, Elsevier

    Dr Joan Genesca

  95. ROLE OF DOPPLER ECHOCARDIOGRAPHY IN THE ASSESSMENT OF PORTOPULMONARY HYPERTENSION IN LIVER TRANSPLANTATION CANDIDATES1

    Article • Transplantation, February 2001, Wolters Kluwer Health

    Dr Joan Genesca

  96. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon

    Article • Journal of Laboratory and Clinical Medicine, January 2001, Elsevier

    Dr Joan Genesca

  97. Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients

    Article • The American Journal of Gastroenterology, June 2000, Wolters Kluwer Health

    Dr Joan Genesca

  98. Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients

    Article • The American Journal of Gastroenterology, June 2000, Wolters Kluwer Health

    Dr Joan Genesca

  99. Relación entre los depósitos de hierro y la diabetes mellitus en pacientes infectados por el virus de la hepatitis C: estudio de casos y controles

    Article • Medicina Clínica, January 2000, Elsevier

    Dr Joan Genesca

  100. Soluble Interleukin-6 Receptor Levels in Liver Cirrhosis

    Article • The American Journal of Gastroenterology, October 1999, Wolters Kluwer Health

    Dr Joan Genesca

  101. Correspondence

    Article • The American Journal of Gastroenterology, October 1999, Wolters Kluwer Health

    Dr Joan Genesca

  102. Article • Digestive Diseases and Sciences, January 1999, Springer Science + Business Media

    Dr Joan Genesca

  103. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis

    Article • The American Journal of Gastroenterology, January 1999, Wolters Kluwer Health

    Dr Joan Genesca

  104. Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis

    Article • The American Journal of Gastroenterology, January 1999, Nature

    Dr Joan Genesca

  105. Correspondence

    Article • The American Journal of Gastroenterology, April 1998, Wolters Kluwer Health

    Dr Joan Genesca

  106. High Levels of Endotoxin Antibodies Contribute to Hyperglobulinemia of Cirrhotic Patients

    Article • The American Journal of Gastroenterology, April 1998, Wolters Kluwer Health

    Dr Joan Genesca

  107. High Prevalence of Hepatitis C Virus Infection in Diabetic Patients

    Article • Diabetes Care, September 1996, American Diabetes Association

    Dr Joan Genesca

  108. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial

    Article • Hepatology, August 1995, Wiley

    Dr Joan Genesca

  109. Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication

    Article • Journal of Hepatology, March 1995, Elsevier

    Dr Joan Genesca

  110. Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b.

    Article • Gut, January 1993, BMJ

    Dr Joan Genesca

  111. Reply

    Article • Gastroenterology, November 1992, Elsevier

    Dr Joan Genesca

  112. Interferon-α in acute posttransfusion hepatitis C:. A randomized, controlled trial

    Article • Hepatology, May 1992, Wiley

    Dr Joan Genesca

  113. Evaluation of anti-HCV positive blood donors identified during routine screening

    Article • January 1992, Springer Science + Business Media

    Dr Joan Genesca

  114. High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

    Article • Annals of Internal Medicine, September 1991, American College of Physicians

    Dr Joan Genesca

  115. Blood-Borne Non-A, Non-B Hepatitis: Hepatitis C

    Article • Seminars in Liver Disease, May 1991, Thieme Publishing Group

    Dr Joan Genesca

  116. Genetic variability of the hepatitis C virus. Sequence analysis of the NS3 and 5'UTR

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  117. Second generation HCV EIA evaluation of acute PT-NANBH

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  118. Serum HCV-RNA in anti-HCV-reactive donors according to RIBA-2, liver histology and infectivity

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  119. Detection of hepatitis B virus DNA in serum by PCR after antiviral therapy in patients with chronic hepatitis B

    Article • Journal of Hepatology, January 1991, Elsevier

    Dr Joan Genesca

  120. Clinical Correlation and Genetic Polymorphism of the Human Immunodeficiency Virus Proviral DNA Obtained after Polymerase Chain Reaction Amplification

    Article • The Journal of Infectious Diseases, November 1990, Oxford University Press (OUP)

    Dr Joan Genesca

  121. A randomized controlled trial of α-interferon in acute postransfusion C hepatitis

    Article • Journal of Hepatology, January 1990, Elsevier

    Dr Joan Genesca

  122. WHAT DO WESTERN BLOT INDETERMINATE PATTERNS FOR HUMAN IMMUNODEFICIENCY VIRUS MEAN IN EIA-NEGATIVE BLOOD DONORS?

    Article • The Lancet, October 1989, Elsevier

    Dr Joan Genesca

  123. Hepatitis D virus RNA in acute delta infection: Serological profile and correlation with other markers of hepatitis D virus infection

    Article • Hepatology, September 1988, Wiley

    Dr Joan Genesca

  124. Lack of HIV transmission after hepatitis B immunoprophylaxis

    Article • Infection, September 1987, Springer Science + Business Media

    Dr Joan Genesca

  125. Hepatitis b virus replication in acute hepatitis B, acute hepatitis B virus-hepatitis delta virus coinfection and acute hepatitis delta superinfection

    Article • Hepatology, May 1987, Wiley

    Dr Joan Genesca

  126. Clinical and serological outcome of acute delta infection

    Article • Journal of Hepatology, January 1987, Elsevier

    Dr Joan Genesca

  127. WHEN SHOULD AT-RISK INFANTS BE BOOSTED WITH HEPATITIS B VACCINE?

    Article • The Lancet, January 1987, Elsevier

    Dr Joan Genesca

  128. Immunoprophylaxis of perinatal transmission of the hepatitis B virus: Efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area

    Article • Journal of Medical Virology, April 1986, Wiley

    Dr Joan Genesca